Van Herk Investments B.V. Takes Notice
In a significant move for Zealand Pharma A/S, the company has disclosed an important update concerning its shareholding. On a recent date, Zealand Pharma (NASDAQ: ZEAL), a company known for its focus on innovative peptide-based medicines, received a formal notification about changes in its shareholder structure.
Details of the Shareholding
Van Herk Investments B.V. has officially reported its shareholdings as of a specified date, revealing ownership of approximately 7,115,191 shares in Zealand Pharma. This stake represents about 9.973% of the total share capital and voting rights of the company, highlighting the growing influence of Van Herk Investments within Zealand Pharma.
Ownership Structure
Understanding the layers of ownership can provide insight into shareholder dynamics. Van Herk Investments B.V. is fully owned by Van Herk Investments THI B.V., which, in turn, is owned entirely by Van Herk Private Equity Investments B.V. Notably, Mr. Adrianus van Herk holds control over Van Herk Private Equity Investments, making him a key figure in the company’s governance.
This ownership hierarchy indicates a significant connection between the investment firm and the operational management of Zealand Pharma, which could potentially inform strategic decision-making and future initiatives of the company.
Voting Rights Exercise
Van Herk Management Services B.V. also plays an essential role, managing and exercising the voting rights for the shares owned by Van Herk Investments B.V. This means that the management entity oversees approximately 9.973% of Zealand Pharma's shares, further reflecting the substantial influence that Van Herk Investments wields within the organization.
About Zealand Pharma
Founded in 1998 and based in Copenhagen, Zealand Pharma A/S has been at the forefront of developing peptide-based medicines. The company boasts a robust portfolio, with more than ten drug candidates progressing through clinical development. Out of these, two products are already on the market, and three others are approaching their final stages of development.
Zealand has formed several key partnerships within the pharmaceutical sector, aiming to leverage collaborative expertise and resources to drive innovation in drug development. The company's dedication to improving patient outcomes through cutting-edge therapies continues to position it as a leader in biotechnology.
Company Contacts and Further Information
For inquiries regarding their investments and future collaborations, Zealand Pharma encourages direct communication with their Investor Relations team. Adam Lange serves as the Vice President of Investor Relations and can be reached for detailed discussions about the latest developments in the company. Likewise, Neshat Ahmadi (Investor Relations Manager) and Anna Krassowska (Vice President of Investor Relations and Corporate Communications) are available to provide insights and assist with investor interests.
To learn more about Zealand Pharma and its innovative projects, individuals are invited to explore the official company website.
Frequently Asked Questions
What is the latest major shareholding announcement from Zealand Pharma?
Zealand Pharma has confirmed that Van Herk Investments B.V. holds a 9.973% share in the company, representing significant influence.
Who is behind Van Herk Investments B.V.?
Van Herk Investments B.V. is wholly owned by Van Herk Investments THI B.V., which is controlled by Van Herk Private Equity Investments B.V., under the ownership of Mr. Adrianus van Herk.
What percentage of shares does Van Herk Investments control?
Van Herk Investments controls approximately 9.973% of Zealand Pharma's total shares and voting rights.
When was Zealand Pharma founded?
Zealand Pharma was established in 1998 and has since been dedicated to the discovery and development of innovative peptide-based medicines.
Where is Zealand Pharma headquartered?
The headquarters of Zealand Pharma is located in Copenhagen, Denmark, with additional operations in the United States.
